SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors

Undoubtedly, the development of COVID-19 vaccines displays a critical step towards ending this devastating pandemic, considering their protective benefits in the general population. Yet, data regarding their efficacy and safety in cancer patients are limited. Herein we provide the initial analysis o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zagouri, Flora, Terpos, Evangelos, Fiste, Oraianthi, Liontos, Michalis, Briasoulis, Alexandros, Katsiana, Ioanna, Skafida, Efi, Markellos, Christos, Kunadis, Elena, Andrikopoulou, Angeliki, Kaparelou, Maria, Koutsoukos, Konstantinos, Gavriatopoulou, Maria, Kastritis, Efstathios, Trougakos, Ioannis P., Dimopoulos, Meletios-Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402928/
https://www.ncbi.nlm.nih.gov/pubmed/34481366
http://dx.doi.org/10.1016/j.breast.2021.08.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402928/
https://www.ncbi.nlm.nih.gov/pubmed/34481366
http://dx.doi.org/10.1016/j.breast.2021.08.017

Ejemplares similares